NAV

Argininosuccinate

Identification

Generic Name
Argininosuccinate
DrugBank Accession Number
DB02267
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 290.2731
Monoisotopic: 290.122634328
Chemical Formula
C10H18N4O6
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UArgininosuccinate lyaseNot AvailableHumans
UArgininosuccinate synthaseNot AvailableThermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aspartic acid and derivatives. These are compounds containing an aspartic acid or a derivative thereof resulting from reaction of aspartic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Aspartic acid and derivatives
Alternative Parents
L-alpha-amino acids / Tricarboxylic acids and derivatives / Guanidines / Amino acids / Propargyl-type 1,3-dipolar organic compounds / Carboxylic acids / Carboximidamides / Organopnictogen compounds / Organic oxides / Monoalkylamines
show 2 more
Substituents
Aliphatic acyclic compound / Alpha-amino acid / Amine / Amino acid / Aspartic acid or derivatives / Carbonyl group / Carboximidamide / Carboxylic acid / Guanidine / Hydrocarbon derivative
show 12 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
KDZOASGQNOPSCU-NTSWFWBYSA-N
InChI
InChI=1S/C10H18N4O6/c11-5(8(17)18)2-1-3-13-10(12)14-6(9(19)20)4-7(15)16/h5-6H,1-4,11H2,(H,15,16)(H,17,18)(H,19,20)(H3,12,13,14)/t5-,6+/m0/s1
IUPAC Name
(2R)-2-[(E)-N''-[(4S)-4-amino-4-carboxybutyl]carbamimidamido]butanedioic acid
SMILES
N[C@@H](CCC\N=C(/N)N[C@H](CC(O)=O)C(O)=O)C(O)=O

References

Synthesis Reference

Steven S. Gross, Owen W. Griffith, "Preventing conversion of citrulline to argininosuccinate to limit pathological nitric oxide overproduction." U.S. Patent US5545625, issued January, 1995.

US5545625
General References
Not Available
PubChem Compound
448718
PubChem Substance
46504554
ChemSpider
395433
PDBe Ligand
AS1
Wikipedia
Argininosuccinic_acid
PDB Entries
1dcn / 1j20 / 1k7w / 1tjw / 6ien

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.37 mg/mLALOGPS
logP-3.2ALOGPS
logP-5.9Chemaxon
logS-2.3ALOGPS
pKa (Strongest Acidic)2.14Chemaxon
pKa (Strongest Basic)11.92Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count10Chemaxon
Hydrogen Donor Count6Chemaxon
Polar Surface Area188.33 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity65.02 m3·mol-1Chemaxon
Polarizability27.55 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.8126
Blood Brain Barrier-0.5775
Caco-2 permeable-0.7638
P-glycoprotein substrateNon-substrate0.5209
P-glycoprotein inhibitor INon-inhibitor0.9576
P-glycoprotein inhibitor IINon-inhibitor0.903
Renal organic cation transporterNon-inhibitor0.8366
CYP450 2C9 substrateNon-substrate0.768
CYP450 2D6 substrateNon-substrate0.7531
CYP450 3A4 substrateNon-substrate0.7719
CYP450 1A2 substrateNon-inhibitor0.8419
CYP450 2C9 inhibitorNon-inhibitor0.9247
CYP450 2D6 inhibitorNon-inhibitor0.9299
CYP450 2C19 inhibitorNon-inhibitor0.885
CYP450 3A4 inhibitorNon-inhibitor0.8201
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9971
Ames testNon AMES toxic0.5696
CarcinogenicityNon-carcinogens0.9502
BiodegradationReady biodegradable0.9012
Rat acute toxicity1.6366 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9474
hERG inhibition (predictor II)Non-inhibitor0.9509
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Argininosuccinate lyase
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Argininosuccinate lyase activity
Specific Function
Not Available
Gene Name
ASL
Uniprot ID
P04424
Uniprot Name
Argininosuccinate lyase
Molecular Weight
51657.505 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Details2. Argininosuccinate synthase
Kind
Protein
Organism
Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
Pharmacological action
Unknown
General Function
Atp binding
Specific Function
Not Available
Gene Name
argG
Uniprot ID
P59846
Uniprot Name
Argininosuccinate synthase
Molecular Weight
44815.725 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at July 02, 2020 13:14